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ABSTRACT 
Heterozygous variants in the arginine-glutamic acid dipeptide repeats gene (RERE) have been shown 
to cause neurodevelopmental disorder with or without anomalies of the brain, eye, or heart 
(NEDBEH). Here we report nine individuals with NEDBEH who carry partial deletions or deleterious 
sequence variants in RERE. These variants were found to be de novo in all cases in which parental 
samples were available. An analysis of data from individuals with NEDBEH suggests that point 
mutations affecting the Atrophin-1 domain of RERE are associated with an increased risk of structural 
eye defects, congenital heart defects, renal anomalies and sensorineural hearing loss when compared 
to loss-of-function variants that are likely to lead to haploinsufficiency. A high percentage of RERE 
pathogenic variants affect a histidine-rich region in the Atrophin-1 domain. We have also identified a 
recurrent two-amino-acid duplication in this region that is associated with the development of a 
CHARGE syndrome-like phenotype. We conclude that mutations affecting RERE result in a spectrum 
of clinical phenotypes. Genotype-phenotype correlations exist and can be used to guide medical 
decision making. Consideration should also be given to screening for RERE variants in individuals 
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INTRODUCTION 
 The arginine-glutamic acid dipeptide repeats gene (RERE; MIM# 605226) encodes a widely-
expressed nuclear receptor coregulator (L. Wang, Rajan, Pitman, McKeown, & Tsai, 2006; Zoltewicz, 
Stewart, Leung, & Peterson, 2004). Acting in a complex with nuclear receptors and other transcription 
factors, RERE can function to inhibit or promote the expression of individual genes including FGF8 
and RARB (Kumar & Duester, 2014; Vilhais-Neto et al., 2010; L. Wang, Charroux, Kerridge, & Tsai, 
2008; Zoltewicz et al., 2004). One of RERE’s roles is to positively regulate retinoic acid signaling in 
multiple tissues during embryonic development (Kumar & Duester, 2014; Vilhais-Neto et al., 2010; 
Vilhais-Neto et al., 2017). 
 The importance of RERE during development was first demonstrated in animal models. Although 
no abnormal phenotypes have been described in mice that are haploinsufficient for RERE, Zoltewicz 
et al. demonstrated that mouse embryos which were homozygous for an Rere null allele (om, 
c.396+2T>A) died around E9.5 with open neural tube defects and signs suggestive of cardiac failure 
(Zoltewicz et al., 2004). A detailed analysis of Rere-null embryos revealed failure of ventralization of 
the anterior neural plate, fusion of the telencephalic and optic vesicle, failure of heart looping and 
irregular partitioning of somites. This provided evidence that RERE plays a critical role in brain, eye 
and heart development as well as embryonic patterning.  
 Schilling et al. and Plaster et al. reported that zebrafish carrying homozygous variants affecting 
rerea, the zebrafish homologue of RERE, had microphthalmia, inconsistent startle response and 
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Schilling et al., 1996). This finding provided additional evidence for the role of RERE in eye 
development and also suggested that RERE may play a role in inner ear development and function.  
 To overcome the early lethality associated with complete loss of RERE function, Kim et al. 
generated an allelic series of mice bearing the om null allele and an eyes3 (c.578T>C, p.(Val193Ala)) 
hypomorphic allele (Kim et al., 2013). Rere
om/eyes3 
embryos and mice had a variety of abnormal 
phenotypes including postnatal growth deficiency, brain hypoplasia, decreased numbers of neuronal 
nuclear antigen (NeuN)-positive hippocampal neurons, abnormal cerebellar morphology, delayed 
maturation and migration of Purkinje cells, ventriculomegaly, microphthalmia, colobomata, hearing 
loss, conotruncal and septal congenital heart defects, spontaneous development of cardiac fibrosis and 
renal agenesis (Fregeau et al., 2016; Kim & Scott, 2014; Kim et al., 2013).   
 Many of the features seen in RERE-deficient mice overlap those associated with 1p36 
deletion syndrome (MIM# 607872) in humans, which is characterized by developmental 
delay, intellectual disability, seizures, vision problems, hearing loss, short stature, distinctive 
facial features, brain anomalies, orofacial clefting, congenital heart defects, cardiomyopathy, 
and renal anomalies (Jordan, Zaveri, & Scott, 2015; Kang et al., 2007; Shapira et al., 1997). 
Since RERE is located within the proximal 1p36 deletion syndrome critical region, Kim et al. 
hypothesized that RERE haploinsufficiency in humans is likely to contribute to many of the 
phenotypes seen in individuals with terminal and interstitial 1p36 deletions that include 
RERE (Jordan et al., 2015; Kim et al., 2013).  
 This hypothesis was supported by Fregeau et al. who identified ten individuals with 
intellectual disability, developmental delay and/or autism spectrum disorder that carried rare, 
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variants were de novo in all cases in which parental DNA samples were available. 
Neurocognitive deficits, hypotonia, seizures, behavioral problems, structural brain anomalies, 
ophthalmologic anomalies, congenital heart defects, and genitourinary abnormalities were 
recurrently documented within this cohort. The genetic syndrome found in these individuals was 
subsequently described as neurodevelopmental disorder with or without anomalies of the brain, eye, 
or heart (NEDBEH; MIM #616975).  
 Here we describe nine unrelated individuals with NEDBEH caused by partial deletions or 
putatively deleterious sequence variants in RERE. An analysis of clinical and molecular data from 
individuals with NEDBEH suggests the existence of novel genotype-phenotype correlations and 
demonstrates that a high percentage of RERE pathogenic variants affect a histidine-rich region in the 
Atrophin-1 domain. We document two individuals who carry a recurrent two-amino-acid duplication 
in this region who fulfill diagnostic criteria for CHARGE syndrome (MIM #214800) but do not carry 
pathogenic variants in CHD7 (MIM # 608892). 
MATERIALS AND METHODS 
Subject Accrual 
 All subjects or their parents/guardians provided informed consent and were enrolled in 
institutional review board-approved research studies. In all cases, the procedures followed were in 
accordance with the ethical standards of the institution’s committee on human research and were in 
keeping with international standards. 
Copy Number Variant Analysis 
 The RERE deletion in Subject 1 was identified by array-based CNV analysis performed on a 




This article is protected by copyright. All rights reserved. 
7 
 
oligonucleotide-based array that included 400,000 probes for the detection of gains or losses of 
genomic material via array-based comparative genomic hybridization and 60,000 SNP probes for the 
detection of absence of heterozygosity (Wiszniewska et al., 2014). 
Exome Sequencing 
 Exome sequencing was performed for all subjects in CLIA or ISO15189 certified laboratories 
with the exception of Subject 2 whose exome sequencing was performed on a research basis. For 
Subject 2, trio exome sequencing was performed on a HiSeq2500 platform (Illumina, San Diego, 
CA). Library prearation was performed using a KAPA Biosystems (Wilmington, MA) library 
preparation kit followed by whole-exome capture using a Roche NimbleGen (Madison, WI) SeqCap 
EZ Exome Kit v3.0/v4.0. Bioinformatics processing was performed  y Colom ia University’s 
Institute for Genomic Medicine using established bioinformatic and trio analysis platforms. All 
sequence variants described in this manuscirpt were confirmed by Sanger sequencing.  
 Throughout the text and tables, nucleotide (cDNA) numbering uses +1 as the A of the ATG 
translation initiation codon in the reference sequence, with the initiation codon as codon 1. All RERE 
variants mentioned in the text have been submitted to the ClinVar database 
(https://www.ncbi.nlm.nih.gov/clinvar/). 
In Silico Prediction of the Effects of Sequence Variants 
 The following programs were used to predict the effects of sequence variants on protein function: 
PolyPhen-2 [HumVar] (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/) and 









 A 2-tailed Fisher exact test (VassarStats statistical package, http://vassarstats.net/tab2x2.html) 
was used to compare the incidences of structural birth defects and sensorineural hearing loss between 
individuals who carried RERE putative loss-of-function variants and individuals who carried point 
mutation that affect the RERE Atrophin-1 domain.   
RESULTS 
 Here, we describe nine individuals who carry partial deletions or putatively deleterious sequence 
variants in RERE (Figure 1). These changes were shown to have arisen de novo in the eight 
individuals for whom parental samples could be obtained. As expected, these changes are rare in the 
general population with none being seen in individuals cataloged in the ExAC browser 
(http://exac.broadinstitute.org/) or gnomAD (gnomad/broadinstitute.org). Brief descriptions of their 
molecular findings and their clinical presentations are provided below and in Tables 1 and 2. Detailed 
clinical histories are available in the Supplementary Materials. All RERE sequence variants reported 
are based on RERE transcript variant 1 (NM_012102.3). Throughout the text and tables, nucleotide 
(cDNA) numbering uses +1 as the A of the ATG translation initiation codon in the reference 
sequence, with the initiation codon as codon 1.  
Subject 1 
 Subject 1 is a 4-year, 3-month-old Hispanic male who carries an approximately 317 kb deletion 
(minimum deletion chr1:8,509,888-8,803,072; maximum deletion chr1:8,497,191-8,813,784; hg19) 
which includes coding exons 1-10 of the RERE gene. These exons encode the first 401 amino acids of 
RERE (Figure 1). No other genes were included in this deletion region. Parental samples were not 
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 Pregnancy was uncomplicated, and he was delivered via repeat caesarian section without incident. 
At birth, he weighed 3.26 kg (43
rd
 centile). His mother has mild cerebral palsy, speech problems and 
learning disabilities, but graduated from a technical college. His father and a paternal aunt have 
bipolar disorder, and a sister had developmental delay as an infant but is currently doing well in 
school. His clinical diagnoses include global developmental delay and mixed receptive-expressive 
language disorder. A hearing evaluation was normal. A brain MRI obtained at 3 years, 11 months of 
age was normal.  
 At 4 years 3 months of age, he weighed 16.3 kg (35
th
 centile) and his height was 100 cm (13
th
 
centile). Physical exam findings included a triangular face, mild plagiocephaly, normal tone and a 
right ankle contracture.  
Subject 2 
 Subject 2 is an 8-month-old Hispanic male who carries a de novo c.248dupA, p.(Ser84Valfs*4) 
variant in RERE. A nuchal translucency scan at 9 weeks and 6 days of gestation revealed a cystic 
hygroma. At 14 weeks of gestation the nuchal translucency was normal at 2.2 mm. Anatomy 
ultrasounds and fetal echocardiography did not identify any structural anomalies. He was born at 38 
weeks of gestation via vaginal delivery. Birth weight was 2.955 kg (20
th
 centile). 
 In the first months of life he had multiple urinary tract infections. Radiographic studies showed no 
evidence of hydronephrosis or vesicoureteral reflux. He was noted to be hypertonic, but his gross 
motor development has been normal: he rolled over at 3 months of age and started sitting on his own 
at 7 months of age.  
 At 8 months of age his length was at the 25
th
 centile, his weight was at the 5
th
 centile and his 
occipital frontal circumference (OFC) was at the 25
th
 centile. On physical examination he was noted 
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downslanted palpebral fissures, synophrys, mild hypoplastic helices, redundant nuchal skin and 
spasticity of all four extremities with upper limbs being more affected than lower limbs.  
Subject 3 
 Subject 3 is a 21-year-old male of European descent who carries a de novo c.4300 T>C, 
p.(Ser1434Pro) missense variant in RERE. Pregnancy was complicated by twin gestation with loss of 
the second twin at 10 weeks of gestation. He was born via vaginal delivery. At birth he weighed 3.402 
kg (54
th
 centile) and was 53.3 cm (97
th
 centile) in length. He rolled over at 6 months of age, sat at 9 
months of age, crawled at 18 months of age and walked at 3 years of age. Parents indicate that he said 
his first words at approximately 9 months of age and that he put two words together between 2 and 3 
years of age.   
 He had an atrial septal defect for which he underwent a transcatheter closure and is currently 
being treated with atenolol for aortic root dilatation. His clinical diagnoses include developmental 
delay, intellectual disability, hypotonia, ataxia, obsessive compulsive disorder, expressive language 
disorder, bilateral ptosis, esotropia, sleep apnea and scoliosis. A brain MRI obtained at 9 years of age 
revealed moderate global volume loss both supratentorially and infratentorially, a thin corpus 
callosum, flattening of the brain stem and a thin rim of sella. Hearing loss evaluations revealed 
chronic tympanic membrane perforation on the right and mild sensorineural hearing loss on the left. 
 At 19 years, 7 months of age his height was 163.3 cm (3
rd
 centile) and his weight was 59.9 kg 
(14
th
 centile). He was noted to have repetitive hand movements, an elongated and myopathic face with 
midfacial retraction, bilateral ptosis, deep-set eyes, a highly arched palate, spatulated thumbs and 
hyperconvexity of his fingernails and toenails. He currently speaks in up to 4 to 5 word sentences and 









 Subject 4 is a 13-year-old female of European descent who carries a de novo c.4303C>T, 
p.(His1435Tyr) missense variant in RERE. Pregnancy was uneventful and she was born at 39 weeks 
of gestation by cesarean section for breech presentation. At birth she weighed 2.980 kg (29
nd
 centile) 
and was 46 cm (5
th
 centile) long with an OFC of 35 cm (83
rd
 centile). She had hypotonia first noted in 
the neonatal period and was ultimately diagnosed with global developmental delay and severe 
intellectual disability. A brain MRI obtained at 5 years of age showed hemispheric cerebellar 
dysplasia with abnormal lobule and fissure orientation in the inferior hemispheres. Onset of puberty 
was noted between 6 and 7 years of age. Treatment for precocious puberty was initiated at 8 years of 
age and continued until she was 13 years old. 
 At 13 years of age her height was 148 cm (10
th
 centile), her weight was 47 kg (55
th
 centile), and 
her OFC was 54 cm (62
nd
 centile). She had a vocabulary of less than 20 words and was not using two-
word phrases. Hearing evaluation was normal. She has frequent temper tantrums.  
Subject 5 
 Subject 5 is a 22-year-old female of Japanese and European ancestry who carries a de novo 
c.4304A>G, p.(His1435Arg) variant in RERE. She was born by induced delivery at 40 2/7 weeks of 
gestation following an uneventful pregnancy. At birth she weighed 3.6 kg (78
th
 centile), her length 
was 53 cm (95
th
 centile) and her OFC was 33 cm (23
rd
 centile). Her Apgar scores were 8 and 9. 
Shortly after birth she was noted to have hypotonia and hypoxia. During her hospitalization she was 
diagnosed with an atrial septal defect and found to have 11 pairs of ribs. She was discharged home at 
14 days of age with supplemental oxygen.  
 Global developmental delay was noted in infancy. At 1.5 years of age, acoustic emittance testing 
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immaturity. Subsequent high frequency auditory brainstem response (ABR) evaluation was normal 
but middle and low frequencies were not tested. She walked and spoke her first word at 5 years of 
age. At 8 years of age she used approximately 25 words. A brain MRI was performed at 2 years of 
age and showed only mildly prominent CSF spaces.  
 At 21 years old, her height was 143 cm (<1
st
 centile, -3.08 SD), her weight was 63.6 kg (73
rd
 
centile), her body mass index (BMI) was 31.1 (99
th
 centile) and her OFC was 55.5 cm (73
rd
 centile). 
She was noted to have upslanted palpebral fissures, large ears with overfolded helices, a right 
preauricular pit, small hands and feet, brachydactyly, and hyperconvex toenails.  
Subject 6 
 Subject 6 is an 8-year, 6-month-old male of Asian Indian descent who carries two de novo 
heterozygous missense variants in RERE, a c.3292C>G, p.(Leu1098Val) variant and c.4304A>T, 
p.(His1435Leu) variant. The phase of these variants is not known. He was also found to carry a de 
novo c.1147C>T, p.(Arg383Trp) variant in the protein phosphatase 2 regulatory subunit, alpha gene 
(PPP2R2A, MIM #604941, NM_002717.3). This variant was predicted to be benign by PolyPhen-2, 
damaging by SIFT, and disease causing by MutationTaster, and has not been seen in control 
individuals in the ExAC Browser or in gnomAD. PPP2R2A is a member of a large family of 
heterotrimeric Ser/Thr phophatases and plays a critical role in homologous recombination repair 
through modulation of ATM phosphorylation (Kalev et al., 2012). PPP2R2A has a probability of loss-
of-function intolerance (pLI) score of 0.96 in the ExAC Browser but has not been associated with a 
specific genetic disorder in humans.  
 He was ultimately diagnosed with global developmental delay, intellectual disability, autism 
spectrum disorder, cerebral palsy, mild bilateral sensorineural hearing loss, bilateral myopia and 
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At 8 years, 6 months of age, his height was 116.4 cm (6
th
 centile), his weight was 22.2 kg (26
th
 
centile) and his OFC was 50.5 cm (22
nd
 centile). On physical exam he was noted to have prominent, 
cupped ears, a triangular-shaped face, mild fifth finger clinodactyly, 2
nd
 toes that override his 1
st
 toes 
bilaterally, and ankle valgus deformities of the feet resulting in pronation for which he wears braces.  
Subject 7 
 Subject 7 was a male of European descent who died at 33 days of age. He carried a de novo 
c.4313_4318dupTCCACC, p.(Leu1438_His1439dup) variant in RERE. This type of variant is not 
amenable to evaluation by PolyPhen-2 or SIFT, and MutationTaster predicts this variant to be a 
polymorphism. However, this duplication is located in the Atrophin-1 domain of RERE and affects a 
histidine-rich region whose amino acid sequence is 100% conserved down to Xenopus and zebrafish. 
We also note that the same variant was found to have arisen de novo in a previously reported 
individual with NEDBEH (Fregeau et al., Subject 2) and in Subject 8 (Fregeau et al., 2016). 
 Pregnancy was complicated by polyhydramnios and gestational diabetes mellitus. He was born 
prematurely at 36 4/7 weeks gestation via spontaneous vaginal delivery. At birth he was flaccid and 
required positive pressure ventilation for apnea and cyanosis. Apgar scores were 2, 4, 7 and 9. He was 
placed on continuous positive airway pressure (CPAP) and transferred to a neonatal intensive care 
unit where he was intubated due to low tone and increased work of breathing. His weight was 2.550 
kg (24
th
 centile), his length was 47 cm (37
th
 centile) and his OFC was 33.5 cm (37
th
 centile). Physical 
exam findings included a flat nasal bridge, a large prominent forehead, bilateral ptosis, left-sided iris 





 digits, widely spaced nipples, hypospadias, and axial hypotonia with normal deep 
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 He was subsequently found to have bilateral choanal atresia, an atrial septal defect, a ventricular 
septal defect, a small patent foramen ovale and a mildly dilated right ventricle. A head ultrasound 
performed on day 3 of life revealed diffuse white matter changes with increased echogenicity and 
concerns for simplified sulcation. A brain MRI performed on the seventh day of life revealed a 
simplified gyral pattern with unusually large ventricles suggestive of delayed brain maturation. 
Multiple punctate periventricular ischemic lesions were also detected along with restricted diffusion 
in the splenium of the corpus callosum.  Audiometry was not performed, but MRI and CT scans 
revealed normal semicircular canals.   
 Over time, he developed heart failure with pulmonary edema and elevated right ventricle and 
diastolic pressures (>50% systemic) suggestive of persistent pulmonary hypertension. He remained 
intubated until his death at 33 days of age. An autopsy confirmed the simplified gyration of cerebral 
cortex and also showed atrophy of the frontal lobes, dysplasia of the inferior olivary and dentate 
nuclei, mild to moderate ventriculomegaly, multifocal neuroglial heterotopia and optic nerve 
hypoplasia. There was also evidence of hypoxic-ischemic damage.  
Subject 8 
 Subject 8 is an 8-year, 3-month-old female of European descent who carries a de novo 
c.4313_4318dupTCCACC, p.(Leu1438_His1439dup) variant in RERE. A truncus arteriosus type I 
defect was identified prenatally along with intrauterine growth retardation and fetal hand posturing. 
She was born at 39 1/7 weeks gestation by emergency cesarean section because of decreased fetal 
heart tones. Apgar scores were 1 and 6. Birth weight was 2.415 kg (3
rd
 centile), length was 47 cm 
(13
th
 centile) and OFC was 32 cm (6
th
 centile).   
 She was subsequently diagnosed with bilateral choanal atresia, right-sided chorioretinal and iris 
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Following surgery, she had neonatal supraventricular tachycardia (SVT) which resolved by 1 year of 
age.  
 She has progressive sensorineural hearing loss and wears a hearing aid in the left ear and has a 
cochlear implant on the right side. A temporal bone CT scan showed bilateral cochlear dysplasia. She 
has been diagnosed with developmental delay and intellectual disability. She has no speech and 
cannot stand or walk without assistance. She has short stature with advanced bone age and has been 
diagnosed with neuromuscular thoracolumbar scoliosis, bilateral hip dysplasia, and bilateral equinus 
contractures. 
  At 8 years, 3 months of age, her height was 114.3 cm (0.4
th
 centile), her weight was 20.4 kg (4
th
 
centile) and her OFC was 47 cm (<1
st
 centile). She had a flattened facial profile, hypertelorism, a 
right-sided iris coloboma, normally set ears with very small lobules and prominent antihelices, a 
broad nasal bridge, a III/VI systolic murmur and bilateral hockey stick palmar creases.  
Subject 9 
 Subject 9 is a 4-year-old female of European descent who carries a de novo c.4391A>G, p.( 
His1464Arg) variant in RERE. She has a twin brother who is healthy and an older brother who was 
diagnosed with dyslexia but is otherwise healthy. She has been diagnosed with developmental delay, 
autism spectrum disorder and obsessive compulsive disorder. Her parents report erratic behavior, 
extreme separation anxiety and difficulty falling asleep and remaining asleep. At her most recent 
physical examination, her height and weight were at the 95
th
 centile and her head circumference was 
at the 50
th
 centile. She was found to have hirsutism affecting the back and arms, synophrys, 









 Here we report nine individuals with NEDBEH caused by partial deletions or putatively 
deleterious sequence variants in RERE. Functional analyses aimed at confirming the effect of these 
variants on RERE function were not performed. Consistent with previous reports of individuals with 
NEDBEH, intellectual disability, developmental delay and/or autism was diagnosed in all individuals 
except Subject 2, who is 8 months old and achieved his early motor milestones on time despite being 
hypertonic, and Subject 7 who died in infancy. Among the six individuals who had brain MRIs, three 
(50%) had structural defects, one (17%) had only mildly prominent CSF spaces, and two (33%) had 
MRIs that were reported as normal for age. Structural eye defects were seen in two individuals in our 
cohort (22%), both of whom had colobomata. Other eye/vision problems identified included myopia, 
anisometropia, astigmatism, exotropia, esotropia, ptosis and optic nerve hypoplasia. Congenital heart 
defects were seen in four individuals (44%) and included septal defects and truncus arteriosus.  
 Some of the medical problems identified in only one individual (1/10, 10%) in the NEDBEH 
cohort reported by Fregeau et al. were also identified in one or more individuals in our cohort 
(Fregeau et al., 2016). These include sensorineural hearing loss which was present in 3 subjects 
(33%), scoliosis which was identified in 2 subjects (22%) and congenital hip dysplasia, which was 
seen in one individual (11%). These medical problems have also been previously reported in 
individuals who carry 1p36 deletions that include RERE (Fregeau et al., 2016). 
Pathogenic variants affecting a histidine rich region of the Atrophin-1 domain of RERE 
 Of the 19 individuals with NEDBEH described here and by Fregeau et al., nine (47%) carry 
sequence variants that affect a histidine-rich region of the Atrophin-1 domain that spans 21 amino 
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conserved down to Xenopus and zebrafish, but the functional significance of this domain is currently 
unknown.  
 Genotype-phenotype correlations 
 Fregeau et al. suggested that point mutations in the Atrophin-1 domain might be associated with a 
more severe clinical presentation (Fregeau et al., 2016). Our study provides additional evidence in 
support of this genotype-phenotype correlation. Among the 19 individuals with NEDBEH described 
here and by Fregeau et al., six (31%) carry putative loss-of-function variants—partial deletions, 
nonsense variants or frameshift variants—and 12 (63%) individuals carry point mutations in the 
Atrophin-1 domain. We evaluated the incidence of structural defects of the brain, eye, heart and 
kidney and sensorineural hearing loss between these two groups (Table 3, Supp. Table S1). The total 
number of structural defects and sensorineural hearing loss seen in individuals with point mutations in 
the Atrophin-1 domain is significantly higher than expected based on the number of structural defects 
seen in individuals with putative loss-of-function variants (p = 0.0004).  
 The increase in severity seen with point mutations in the Atophin-1 domain may be due to the 
generation of an abnormal protein product that functions in a dominant negative fashion by 
antagonizing the function of the wild-type gene product within the same cell. This hypothesis is 
supported by the fact that the phenotypes seen in individuals with point mutations overlap those of 
Rere
om/eyes3 
mice who carry both a null and a hypomorphic allele of Rere (Fregeau et al., 2016; Kim et 
al., 2013).  
 Our ability to identify genotype-phenotype correlation is currently limited by the relatively small 
number of patients that have been described who carry pathogenic variants in RERE. As additional 
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 Studies of RERE-deficient
 
mice on different genetic backgrounds have shown that the penetrance 
of some RERE-related phenotypes, such a congenital heart defects, are highly dependent on genetic 
factors that have yet to be identified (Kim et al., 2013). Variations in the phenotypes of individual 
RERE-deficient mice on the same genetic background suggest that epigenetic, environmental and/or 
stochastic factors also exist that can influence the penetrance and severity of individual phenotypes. 
These findings provide hope for the development of penetrative and therapeutic interventions, but also 
suggest the need for caution when providing individuals and families with prognostic information 
based largely on genotype-phenotype correlations.  
 An RERE variant in CHD7-negative CHARGE syndrome 
 Two individuals within our cohort carry the same de novo c.4313_4318dupTCCACC, p.( 
Leu1438_His1439dup) variant in RERE. This same variant also arose de novo in a previously reported 
15-month-old male (Fregeau et al., Subject 2) who had a unilateral iris coloboma, a ventricular septal 
defect, patent ductus arteriosus that was surgically closed, anomalous pulmonary venous return, 
choanal atresia, simple ears, cryptorchidism, a right-sided multicystic kidney, short stature, 
microcephaly, developmental delay and brain anomalies that included a thin corpus callosum, 
ventriculomegaly, incompletely folded hippocampi, and severely diminished white matter-volume 
(Fregeau et al., 2016). 
 Due to their clinical presentations, all three of these individuals were originally suspected to have 
CHARGE syndrome (Coloboma, Heart defects, choanal Atresia, Retarded growth and 
development, Genital abnormalities, and Ear anomalies) which is most commonly caused by 
heterozygous variants in CHD7 (Hall, 1979; Hittner, Hirsch, Kreh, & Rudolph, 1979; Vissers et al., 
2004). Indeed, all of these individuals fulfill the diagnostic criteria for CHARGE syndrome proposed 
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was undertaken only after screening of the CHD7 gene failed to reveal a causative variant. This 
suggests that consideration should be given to sequencing RERE, or testing for the 
c.4313_4318dupTCCACC variant, in individuals who meet diagnostic criteria for CHARGE 
syndrome but do not have pathogenic variants in CHD7.  
 Although RERE and CHD7 are not known to interact, both function to regulate the transcription 
of other genes and are widely expressed in the developing embryo (Bouazoune and Kingston, 2012; 
Lalani et al., 2006; Sanlaville et al., 2006; Zoltewicz et al., 2004). The overlapping phenotypes seen in 
individuals with deficiency of RERE and CHD7 suggest that they may regulate the expression of a 
common set of genes in the developing embryo or that their gene targets may function in the same 
molecular pathways. In support of this hypothesis, we note that RERE has been show to positively 
regulate retinoic acid signaling during embryonic development (Kumar & Duester, 2014; Vilhais-
Neto et al., 2010; Vilhais-Neto et al., 2017). Although, CHD7 has not been shown to regulate retinoic 
acid signaling, modulation of retinoic acid signaling has been shown to prevent in vivo inner ear and 
in vitro neural stem cell defects caused by CHD7 deficiency (Micucci et al., 2014).  
 In addition, RERE has also been shown to stimulate Notch target gene expression, including the 
expression of Hes genes, by preventing degradation of the Notch intracellular domain (NICD) (H. 
Wang, Gui, Rallo, Xu, & Matise, 2017). Similarly, CHD7 is required for the full induction of Hes5 in 
quiescent neural stem/progenitor cells (NSCs) and loss of CHD7 function lead to decreased 
expression of the Notch ligand JAG1 in the developing inner ear (Hurd, Micucci, Reamer, & Martin, 
2012; Jones et al., 2015).   
 Conclusions 
 Individuals carrying pathogenic variants in RERE can present with a range of clinical phenotypes. 
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disability, and autism—while others have a variety of structural birth defects involving the brain, eye, 
ear, craniofacial structures, heart, kidney and skeleton. Genotype-phenotype correlations exist and 
may help guide medical management and surveillance. Additionally, individuals who carry the 
c.4313_4318dupTCCACC, p.( Leu1438_His1439dup) variant in RERE share overlapping clinical 
features similar to that seen in CHARGE syndrome. Individuals who are suspected of having 
CHARGE syndrome but do not carry variants in CHD7 should be evaluated for pathogenic variants in 
RERE. 
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FIGURE LEGENDS 
Figure 1 A-E) Photos of Subjects 3, 5, 6 (at six years of age), 7 (postmortem) and 8. As previously 
reported, a consistent pattern of dysmorphic features is not seen among individuals with NEDBEH 
(Fregeau et al., 2016). F) Deletions and sequence variants identified in Subjects 1-9 and previously 
published individuals with NEDBEH. The locations of the RERE deletions and sequence variants 
reported in individuals with NEDBEH are shown in relation to the protein domains of RERE. 
Deletions and sequence variants found in Subjects 1-9 are shown in red if only a single variant was 
detected and blue if two variants were detected. Previously published sequence variants are shown in 
black. A high percentage of RERE pathogenic variants affect a 21 amino acid (amino acids 1425 to 
1445), histidine-rich region of the Atrophin-1 domain. Nucleotide (cDNA) numbering uses +1 as the 












Table 1  RERE deletions and sequence variants identified in Subjects 1-9  
















Minimum deletion (hg19) 
chr1:8,509,888-8,803,072 
Maximum deletion (hg19) 
chr1:8,497,191-8,813,784 
N/D N/A N/A N/A N/A 

















De novo Possibly 
Damaging 




De novo Probably 
Damaging 




De novo Possibly 
Damaging 
Tolerated Disease Causing No 
c.4304A>T 
p.(His1435Leu) 
De novo Probably 
Damaging 












De novo Benign Tolerated Disease Causing No 
a = Based on RERE transcript variant 1[NM_012102.3].  Nucleotide (cDNA) numbering uses +1 as 
the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as 
codon 1. 
b = This amino acid is altered to a Ser (p.Pro1049Ser) in 10/113338 alleles in gnomAD. 
c = MutationTaster classifies all variants as either “Disease Causing” or “Polymorphism”.  These 
classifications do not indicate that the variant has been shown to cause disease or that the variant is 
found at a frequency ≥1%. 
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Table 2  Summary of clinical findings in subjects 1-9 
 S1 S2 S3 S4 S5 S6 S7 S8 S9 




+ - + + + + N/A + + 
Hypotonia - -  + + + - + - - 
Abnormal brain  
MRI 
- N/D + + -** - + N/D N/D 
Structural eye 
anomalies 
- - - - - - + + - 
Sensorineural 
hearing loss 
- - + - - + N/D + - 
Choanal atresia - - - - - - + + - 
Congenital heart 
defects 
- - + - + - + + - 
Renal anomalies - -* - - - - - - - 
Scoliosis - - + - - - - + - 
          
F = Female, M = Male, - = Not reported, + = Reported, N/A = Not applicable, N/D = Not done 
* = subject had multiple urinary tract infections during the first few months of life but radiographic 
studies showed no evidence of hydronephrosis or vesicoureteral reflux 
** = mildly prominent CSF spaces  
Table 3  Statistical comparison of the incidence of structural birth defects and sensorineural hearing 





in the Atrophin-1 
domain 
p value  
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Eye anomalies 0/6 (0%) 6/12 (50%) 0.11 
Congenital heart defects 1/6 (17%) 7/12 (58%) 0.15 
Renal anomalies 0/6 (0%) 2/12 (17%)  0.53 
Sensorineural hearing loss 0/6 (0%) 4/11 (36%) 0.24 
Number of defects per 
individual 
0.33 (2/6) 2.25 (27/12) 0.0004** 
* = Partial deletions, stop-gains variants or frameshift variants 
** = Based on the total number of defects that could have been identified in each group 
 
Table 4  Individuals with the RERE c.4313_4318dupTCCACC, p.L1438_H1439dup variant meet 
diagnostic criteria for CHARGE syndrome* 
 CHARGE syndrome Fregeau et al. 
Subject 2 
Subject 7 Subject 8 
Major 
criteria 





chorioretinal and iris 
colobomas 
Choanal atresia or 
cleft palate 






















- - Progressive 
sensorineural 
hearing loss 


















of cerebral cortex, 
atrophy of the frontal 
lobes, dysplasia of 
the inferior olivary 














genital anomalies  
Cryptorchidism Hypospadias - 
Heart or esophagus 
malformation 
VSD, PDA, APVR VSD, PFO 
 
Truncus arteriosus 
Renal anomalies Right-sided 
multicystic kidney 






Contractures of the 







* The presence of two major and any number of minor criteria is required to fulfill diagnostic criteria 
for CHARGE syndrome as described by Hale, et al., 2016. 
- = not documented, APVR = anomalous pulmonary venous return, N/A = Not applicable, PDA = 
patent ductus arteriosus, PFO = patent foramen ovale, VSD = ventricular septal defect. 
 
 
